UK markets closed

TC Biopharm (Holdings) Plc (TCBP)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.8698+0.0198 (+2.33%)
At close: 04:00PM EDT
0.8840 +0.01 (+1.63%)
After hours: 07:31PM EDT

TC Biopharm (Holdings) Plc

Maxim 1
2 Parklands Way Holytown
Motherwell ML1 4WR
United Kingdom
44 14 1433 7557

Full-time employees41


TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Corporate governance

TC Biopharm (Holdings) Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.